Literature DB >> 21812172

Using the North Dakota Immunization Information System to determine adolescent vaccination rates and uptake.

Keith LoMurray1, Molly Sander.   

Abstract

OBJECTIVES: We described the uptake and coverage rates of meningococcal conjugate vaccine (MCV4); tetanus-diphtheria-acellular pertussis vaccine (Tdap); and quadrivalent human papillomavirus vaccine (HPV4) in North Dakota using the North Dakota Immunization Information System (NDIIS).
METHODS: We analyzed all available MCV4, Tdap, and HPV4 doses given after vaccine licensure and through December 31, 2009, obtained from the NDIIS to identify trends and patterns in vaccine administration. We analyzed all data by administration date, age group, and health-care provider type. We also calculated missed opportunities to complete all recommended vaccines among vaccinated adolescents.
RESULTS: For adolescents aged 13-17 years, 69.2% had > or = 1 dose of Tdap and 62.8% had > or = 1 dose of MCV4. Of females aged 13-17 years, 42.8% initiated the HPV4 vaccination series and 24.9% received > or = 3 HPV4 doses. Only 48.7% of males aged 13-17 years received both Tdap and MCV4 at the same visit, and only 11.5% of females aged 13-17 years received Tdap, MCV4, and HPV4 doses at the first visit.
CONCLUSIONS: The NDIIS is useful in tracking adolescent vaccine uptake. The immunization rates for all three routinely recommended adolescent vaccines are rising in North Dakota, although at different paces. Providers should be educated about the importance of not missing opportunities to vaccinate, and school-based vaccination clinics should be used to reach adolescents who are less likely to have preventive care visits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812172      PMCID: PMC3113433          DOI: 10.1177/00333549111260S210

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  25 in total

1.  Additional health care visits needed among adolescents for human papillomavirus vaccine delivery within medical homes: a national study.

Authors:  Cynthia M Rand; Peter G Szilagyi; Christina Albertin; Peggy Auinger
Journal:  Pediatrics       Date:  2007-09       Impact factor: 7.124

2.  Variation in provider vaccine purchase prices and payer reimbursement.

Authors:  Gary L Freed; Anne E Cowan; Sashi Gregory; Sarah J Clark
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

Review 3.  Mandates for adolescent immunizations: recommendations from the National Vaccine Advisory Committee.

Authors: 
Journal:  Am J Prev Med       Date:  2008-08       Impact factor: 5.043

4.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger
Journal:  MMWR Recomm Rep       Date:  2007-03-23

5.  Parental vaccine safety concerns in 2009.

Authors:  Gary L Freed; Sarah J Clark; Amy T Butchart; Dianne C Singer; Matthew M Davis
Journal:  Pediatrics       Date:  2010-03-01       Impact factor: 7.124

6.  National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines.

Authors:  Cynthia M Rand; Laura P Shone; Christina Albertin; Peggy Auinger; Jonathan D Klein; Peter G Szilagyi
Journal:  Arch Pediatr Adolesc Med       Date:  2007-03

7.  Increasing immunization coverage.

Authors:  Lawrence D Hammer; Edward S Curry; Allen D Harlor; James J Laughlin; Andrea J Leeds; Herschel R Lessin; Chadwick T Rodgers; Deise C Granado-Villar; Jeffrey M Brown; William H Cotton; Beverly Marie Madry Gaines; Thresia B Gambon; Benjamin A Gitterman; Peter A Gorski; Colleen A Kraft; Ronald Vincent Marino; Gonzalo J Paz-Soldan; Barbara Zind
Journal:  Pediatrics       Date:  2010-05-31       Impact factor: 7.124

8.  Adolescent immunizations: missed opportunities for prevention.

Authors:  Grace M Lee; Suchita A Lorick; Elizabeth Pfoh; Ken Kleinman; Daniel Fishbein
Journal:  Pediatrics       Date:  2008-10       Impact factor: 7.124

9.  Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States.

Authors:  Sara E Forhan; Sami L Gottlieb; Maya R Sternberg; Fujie Xu; S Deblina Datta; Geraldine M McQuillan; Stuart M Berman; Lauri E Markowitz
Journal:  Pediatrics       Date:  2009-11-23       Impact factor: 7.124

10.  National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-09-18       Impact factor: 17.586

View more
  5 in total

1.  Trends in Michigan early adolescent immunization: 2006-2008.

Authors:  Erin Rees-Clayton; JoLynn P Montgomery; Kyle S Enger; Matthew L Boulton
Journal:  Am J Public Health       Date:  2012-07-19       Impact factor: 9.308

2.  Evaluation of the frequency of immunization information system use for public health research.

Authors:  Eileen A Curran; Robert A Bednarczyk; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2013-02-19       Impact factor: 3.452

3.  Uptake of meningococcal vaccine in Arizona schoolchildren after implementation of school-entry immunization requirements.

Authors:  Jennifer E Simpson; Rebecca A Hills; Deborah Allwes; Lisa Rasmussen
Journal:  Public Health Rep       Date:  2013 Jan-Feb       Impact factor: 2.792

4.  Voluntarily Reported Immunization Registry Data: Reliability and Feasibility to Predict Immunization Rates, San Diego, California, 2013.

Authors:  Zachary J Madewell; Robert B Wester; Wendy W Wang; Tyler C Smith; K Michael Peddecord; Jessica Morris; Heidi DeGuzman; Mark H Sawyer; Eric C McDonald
Journal:  Public Health Rep       Date:  2017-04-05       Impact factor: 2.792

5.  Improving immunization delivery using an electronic health record: the ImmProve project.

Authors:  David G Bundy; Nichole M Persing; Barry S Solomon; Tracy M King; Peter N Murakami; Richard E Thompson; Lilly D Engineer; Christoph U Lehmann; Marlene R Miller
Journal:  Acad Pediatr       Date:  2013-03-14       Impact factor: 3.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.